Phibro Animal Health Corporation develops, manufactures and sells livestock medicines, vaccines, nutritional products, trace minerals and specialty chemical ingredients. Its three reporting segments are Animal Health, Mineral Nutrition and Performance Products. Fiscal years end June 30; financial amounts below are in U.S. dollars.
Loading the company summary…
A snapshot of what PHIBRO ANIMAL HEALTH CORP owns and owes at a point in time.
Read the company’s balance sheet in the original annual reports below.
Browse original filingsSee the original statement for its reporting period, currency, and unit.
3 reports in this collection
| Report period | Filed with SEC | Form | Source |
|---|---|---|---|
| Jun 30, 20240001558370-24-012517 | Aug 28, 2024 | 10-K | Open 10-Ksec.gov |
| Jun 30, 20250001558370-25-011776 | Aug 27, 2025 | 10-K | Open 10-Ksec.gov |
| Jun 30, 20260001104659-26-101493 | Aug 26, 2026 | 10-K | Open 10-Ksec.gov |
Dates describe the filing metadata. Figures and reporting periods should be checked against the original statement. SEC links open in a new tab.
Phibro entered fiscal 2027 with a larger animal-health business and stronger reported profitability, but weaker cash conversion and substantial regulatory dependencies. Fiscal 2026 revenue reached $1.518 billion and GAAP net income $99.7 million. The improvement included a full year of the acquired Zoetis portfolio, better product mix and pricing, lower acquisition expenses, and tariff-recovery accounting—not simply organic demand growth. Inventory investment and higher capital spending left only $9.9 million of operating cash flow after cash capital expenditure, below annual dividends. Expanded revolving capacity provides financing flexibility, not additional cash on hand. Brazilian virginiamycin approval, the unresolved Mecadox proceedings and the planned Chicago Heights manufacturing transfer remain important uncertainties. Based on the listed sources through October 24, 2026, these conclusions leave the tariff disclosures unreconciled and their reconciled net earnings contribution unknown. Later operating outcomes are not verified.
Sources: 10-K · 2026-06-30 · 10-K · 2025-06-30 · EX-99.1 · 2026-08-26 · 8-K · 2026-04-28
Phibro serves approximately 4,800 customers in 90 countries through about 790 product lines. Animal Health generated approximately 77% of fiscal 2026 sales and includes medicated feed additives, nutritional specialties, vaccines and ethanol-processing products. The remaining businesses supply trace minerals and specialty chemical ingredients. Regulatory registrations, manufacturing knowledge and technical support underpin its competitive position. Customers generally purchase through orders rather than long-term delivery commitments, so distributor inventory movements can affect reported sales independently of end-user demand. Medicated products represented approximately 54% of revenue, making antimicrobial restrictions a company-wide economic exposure.
Sources: 10-K · 2026-06-30
Fiscal 2026 revenue was $1,518.093 million, compared with $1,296.215 million in 2025. Acquired-product revenue rose to $358.2 million from $208.2 million because the prior year included operations only after the October 31, 2024 closing. Reported growth therefore is not an organic-growth measure. Management also cites stronger legacy-product demand, favorable mix and higher selling prices. GAAP operating income increased to $194.396 million and net income to $99.720 million. Lower acquisition expenses and the absence of prior-year inventory write-offs helped the comparison. Mineral Nutrition faced unit-cost pressure, while weaker personal-care demand reduced Performance Products earnings.
The annual report records an $8.5 million tariff-recovery reduction in cost of goods sold for both the three and twelve months ended June 30, 2026, while the same-day earnings release describes a net $4.3 million tariff-recovery benefit to gross profit for the three months ended June 30, 2026. The annual's recognized recovery component is not a reconciled net benefit, and the release's net gross-profit benefit is not a net-income amount. These are not additive, and the supplied records do not reconcile their different descriptions; their reconciled net earnings contribution remains unknown. No offset or cash collection is inferred. Adjusted EBITDA of $254.971 million does not remove the tariff benefit. Adjusted net income also uses a changed definition that excludes acquisition-related property step-up depreciation, with applicable prior periods conformed.
Sources: 10-K · 2026-06-30 · 10-K · 2025-06-30 · EX-99.1 · 2026-08-26
Operating cash flow fell to $68.954 million in fiscal 2026 from $80.124 million in 2025, despite higher profit. Inventory consumed $86.338 million of cash; management attributes the accumulation principally to acquisition-related quantities purchased for anticipated tariffs and forecast demand. Cash capital expenditure rose to $59.088 million, leaving $9.866 million before acquisitions and financing. Dividends of $19.463 million exceeded that residual. Net revolving borrowings supplied $29 million, while term-loan repayments used $16.250 million. Inventory sell-through and collection of tariff claims are not established outcomes.
Sources: 10-K · 2026-06-30
At June 30, 2026, cash and short-term investments totaled $81.994 million, separate from $737.875 million of term-loan and revolving principal. Insurance financing and operating leases are additional obligations outside that principal measure. The April 28 amendment increased revolving commitments to $435 million; the annual report subsequently reported $316.917 million available, subject to restrictions. That capacity is not cash. Phibro reported covenant compliance at year-end but did not disclose actual covenant ratios or headroom. Net interest expense increased to $44.429 million, principally reflecting acquisition financing and expiration of a favorable swap.
Sources: 10-K · 2026-06-30 · 8-K · 2026-04-28
Brazilian virginiamycin generated approximately $27 million of fiscal 2026 sales, but therapeutic approvals remained pending at the August 26 filing date following restrictions on performance-enhancement uses. Mecadox, with approximately $21 million of annual sales, remained available while withdrawal proceedings and litigation were unresolved. Neither eventual approval nor a final sales ban is established. Some products depend on single plants or approved suppliers; conflict exposure in Israel, input-cost pass-through and the planned Chicago Heights transfer add operating uncertainty. BFI's approximately 90.3% voting control also limits public shareholders' influence.
Sources: 10-K · 2026-06-30
The latest included annual report and earnings announcement were both filed August 26, 2026. They describe an August decision to close Chicago Heights, with production expected to end in summer 2027, and conditional fiscal 2027 guidance. These are subsequent-to-year-end disclosures, not evidence of developments after the annual filing. This analysis uses the listed sources through October 24, 2026. Subsequent regulatory approvals, closure progress, dividend payments and guidance revisions are not verified.
Sources: 10-K · 2026-06-30 · 8-K · 2026-08-26 · EX-99.1 · 2026-08-26
USD 1.518093 bn
FY2026 · GAAP · consolidated · Attribution: consolidated · Reported currency
| Fiscal year | Value | YoY |
|---|---|---|
| 2026 | USD 1.518093 bn | — |
Consolidated net sales after variable consideration; includes billed shipping and handling and excludes sales-based taxes.
Sources: 10-K · 2026-06-30
USD 1.296215 bn
FY2025 · GAAP · consolidated · Attribution: consolidated · Reported currency
| Fiscal year | Value | YoY |
|---|---|---|
| 2025 | USD 1.296215 bn | — |
Consolidated net sales after variable consideration; acquired operations included from October 31, 2024.
Sources: 10-K · 2026-06-30
USD 1.017679 bn
FY2024 · GAAP · consolidated · Attribution: consolidated · Reported currency
| Fiscal year | Value | YoY |
|---|---|---|
| 2024 | USD 1.017679 bn | — |
Consolidated net sales after variable consideration; excludes the subsequently acquired Zoetis portfolio.
Sources: 10-K · 2026-06-30
USD 99.72 m
FY2026 · GAAP · consolidated · Attribution: consolidated · Reported currency
| Fiscal year | Value | YoY |
|---|---|---|
| 2026 | USD 99.72 m | 106.6% |
| 2025 | USD 48.264 m | 1897.7% |
| 2024 | USD 2.416 m | — |
Consolidated income after interest, foreign-currency results and income taxes.
Sources: 10-K · 2026-06-30
USD 68.954 m
FY2026 · GAAP · consolidated · Attribution: consolidated · Reported currency
| Fiscal year | Value | YoY |
|---|---|---|
| 2026 | USD 68.954 m | -13.9% |
| 2025 | USD 80.124 m | -8.5% |
| 2024 | USD 87.594 m | — |
Cash-flow-statement operating cash flow after changes in operating assets and liabilities, net of business acquisition.
Sources: 10-K · 2026-06-30
Reading times are estimates for the English text. Financial tables and charts may take additional time.
